Notification of Interim Results
August 16 2010 - 2:00AM
UK Regulatory
TIDMATD
RNS Number : 0856R
Asterand PLC
16 August 2010
+--------------------------------------------+----------------------+
| For Immediate Release | 16 August 2010 |
+--------------------------------------------+----------------------+
ASTERAND PLC
('Asterand' or 'the Company')
Notification of Interim Results
Date: Thursday 26 August 2010
Asterand plc ("Asterand" or the "Group" - LSE: ATD), a leading supplier of human
tissue based solutions to pharmaceutical and biotechnology companies engaged in
drug discovery research will announce its Interim Results for the six months
ended 30 June 2010 on Thursday 26 August 2010.
- Ends -
Contacts:
+------------------------------+--------------------------------------+
| Asterand plc | |
+------------------------------+--------------------------------------+
| Martyn Coombs, Chief | Tel: + 44 (0) 1763 211 600 / + 1 |
| Executive Officer | (313) 263-0960 |
+------------------------------+--------------------------------------+
| John Stchur, Chief Financial | As above |
| Officer | |
+------------------------------+--------------------------------------+
| | |
+------------------------------+--------------------------------------+
| Buchanan Communications | |
+------------------------------+--------------------------------------+
| Lisa Baderoon / Mark Court / | Tel: +44 (0) 20 7466 5000 |
| Isabel Podda | |
+------------------------------+--------------------------------------+
| | |
+------------------------------+--------------------------------------+
| Daniel Stewart & Company plc | |
+------------------------------+--------------------------------------+
| Martin Lampshire | Tel: +44 (0) 20 7776 6550 |
+------------------------------+--------------------------------------+
About ASTERAND
Asterand plc is a leading supplier of high quality human tissue and tissue-based
services. Our comprehensive approach to human tissue and research services
offers pharmaceutical, biotech and diagnostic companies the unique opportunity
to have one company meet all of their human biomaterial needs along the
continuum of drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and biotechnology
companies to take safer and more effective drugs into the market. For more
information about Asterand or BioSeek, go to www.asterand.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSFFFIDFSSEIA
Bioseek (LSE:ATD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Nov 2023 to Nov 2024
